welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
-
Early Onset of Dysplasia in Polyps in Children with Familial Adenomatous Polyposis: Case Report and Literature Revie...Familial adenomatous polyposis (FAP) is ...
-
Evaluation of Management of Desmoid Tumours Associated with Familial Adenomatous Polyposis in Dutch PatientsBACKGROUND : The optimal treatment of de...
-
Ileal Pouch-Anal Anastomosis: Points of ControversyRestorative proctocolectomy with ileal p...
-
Congenital Hypertrophy Retinal Pigment Epithelium as a Manifestation of Colon CancerCongenital hypertrophy retinal pigment e...
-
Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer CellsThe discovery of new bioactive compounds...
-
Let’s Get Clinical: Health Advocacy + an F.A.P. Clinical Trialhttps://www.youtube.com/watch?v=LbeqxDfv...